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Abstract:  Non-invasive depth-resolved measurement of hemoglobin 
oxygen saturation (SaO2) levels in discrete blood vessels may have 
implications for diagnosis and treatment of various pathologies. We 
introduce a novel Dual-Wavelength Photothermal (DWP) Optical 
Coherence Tomography (OCT) for non-invasive depth-resolved 
measurement of SaO2 levels in a blood vessel phantom. DWP OCT SaO2 is 
linearly correlated with blood-gas SaO2  measurements. We demonstrate 
6.3% precision in SaO2  levels measured a phantom blood vessel using 
DWP-OCT with 800 and 765 nm excitation wavelengths. Sources of 
uncertainty in SaO2 levels measured with DWP-OCT are identified and 
characterized. 
©2011 Optical Society of America 
OCIS codes:  (170.1470) Blood or tissue constituent monitoring; (170.4500) Optical 
Coherence Tomography; (120.5050) Phase measurement, (170.6510) Spectroscopy, tissue 
diagnostics; (300.1030) Absorption 
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Tissue oxygenation is an important physiological parameter. Abnormal oxygenation of 
tissues and blood has been implicated in a number of diseases preceding irreversible tissue 
damage including cancer, inflammatory and infectious processes, diabetic retinopathy, 
choroidal disorders, stroke and vascular dementia among others [1]. Tissue oxygenation 
levels have been measured invasively and non-invasively. 
Optical methods have recently attracted significant interest for non-invasive assessment 
of SaO2 levels due to the inherent ability to provide high temporal and spatial resolution. 
Distinct differences in the absorption spectra between oxy- and deoxy-hemoglobin in the 
visible and infrared (IR) spectral regions underlie spectroscopic methods for non-invasive 
assessment of in vivo  hemoglobin oxygen saturation levels [2–11]. Because these 
spectroscopic methods provide mean arterial and venous [2–8] and arterial [9–11] SaO2 
levels averaged over a relatively large volume of tissue, longitudinal and lateral spatial 
specificity to identify a damaged tissue volume is compromised. Assessment of in vivo SaO2 
levels with higher longitudinal and lateral spatial specificity is required for early diagnosis 
and longitudinal monitoring of many diseases including cancer of epithelial tissues, local 
inflammatory and infectious processes, retinopathy, choroidal eye disorders and stroke. For 
example, the human retina is only 200-300 µm thick and consists of many well defined 
physiological longitudinal layers and has two independent vascular oxygen supplies (retina 
and choroid). Because the choroidal vascular supply provides a ten-fold higher blood flow 
than the retinal supply, methods without longitudinal or depth-resolved specificity can 
provide SaO2 levels that are difficult to interpret. 
Spectral Fourier Domain Optical Coherence Tomography (FD OCT) [12,13] can provide 
simultaneously high depth-resolved specificity and temporal resolution and has been applied 
for assessing blood oxygenation levels [14–18]. Although SaO2 measurements with Spectral 
OCT in the visible range was reported in phantoms where absorption of hemoglobin is 
maximal [17], in the near infrared spectrum, which provide increased depth penetration, only 
a correlation with SaO2 levels has been demonstrated [16,18]. Spectral OCT in the visible 
range is limited to probing superficial tissue depths of a few hundred microns and faces 
technical challenges to monitor ocular disorders due to high sensitivity of retinal 
photoreceptors and stimulation of the occipital lobe of the cerebral hemisphere. Challenges 
to apply spectral OCT to measure SaO2 levels are: 1) relatively low absorption of infrared 
light by oxy-/deoxy-hemoglobin (6% energy absorption through a 300 µm diameter blood 
vessel at the isobestic 800 nm wavelength); 2) trade-off between spectral and depth-resolved 
resolutions [13,19]; and 3) high signal variability due to speckle interference effects. 
Instrumentation where phase changes in a sample are induced by absorption of single-
wavelength excitation light and measured with phase sensitive (PhS) OCT [20–23] are 
known as Photothermal OCT [24–27]. Photothermal OCT was used for detection of contrast 
agents in vitro [25], in live cells [26] and in ex vivo tissues [24,27] for early cancer [26,27] 
and atherosclerotic plaques [24] diagnosis. In this paper, we introduce a Dual-Wavelength 
Photothermal OCT (DWP-OCT) that uses excitation and probe light in the near infrared 
spectral region for depth-resolved SaO2 monitoring in tissue phantoms. Our approach was 
applied to depth-resolved measurement of graded SaO2 levels in phantoms and does not 
suffer from the high signal variability of spectral OCT approaches. 
2. Materials and Methods 
The experimental setup for our DWP-OCT (Fig. 1) system to measure SaO2 levels contains 
three major components: 1) excitation laser (800 nm or 765 nm) and fiber delivery system to 
induce nanometer-scale optical pathlength changes in the blood sample; 2) sample consisting 
of a non-absorbing polytetrafluoroethylene (PTFE) conduit containing blood with variable  
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Fig. 1. Dual Wavelength Photothermal (DWP)-OCT. A tunable Ti:Al2O3 laser was utilized as 
an excitation source (765 and 800 nm). Excitation laser light was intensity modulated at 42 
Hz with a mechanical chopper and delivered to the blood sample through a multimode 50 µm 
core-diameter fiber (NA = 0.22). Relative intensity of excitation laser light on the blood 
sample was calibrated with a 4% partial reflector. Probe OCT light (1328 nm) emitted from a 
single mode fiber was focused on the blood sample from the topside with a GRIN lens. A 
reference reflector (5%) provides the OCT reference optical signal. Inset in the upper right 
corner shows absorption spectra of oxy- and deoxy-hemoglobin. Dashed lines indicate laser 
excitation wavelengths (765 nm and 800 nm) utilized in the reported experiments. 
graded SaO2  levels; and 3)  Phase Sensitive (PhS) OCT  system [23] to measure SaO2-
dependent optical pathlength changes induced by excitation laser light. 
The ability of PTFE tubing to maintain a constant blood oxygenation level was tested 
using a commercial avoximeter (ITC, 1000E, Edison, NJ). Blood with SaO2 = 97.6% was 
placed in the PTFE tubing at room temperature for 230 min; after removal, avoximeter-
measured SaO2 level showed a 1.7% decrease to 95.9%. 
Phase measurements provided by DWP-OCT are associated with optical pathlength (op) 
changes in response to dual-wavelength (765 nm and 800 nm) excitation of a blood sample. 
Optical pathlength changes (op = φλ/(4π)) in the sample are induced by light absorption of 
oxy- and deoxy-hemoglobin in blood, where φ is measured phase change at a specific depth 
and λ = 1328 nm is central wavelength of the DWP-OCT system. Measurement of op at 765 
nm and 800 nm laser excitation wavelengths is used to compute SaO2 levels in blood using 
an analytical model described in section 2.5 below. 
2.1 Sample Preparation 
Fresh porcine arterial blood was collected, placed in a sealed container and stored at 4°C. To 
prevent clotting, 50 units of heparin per 50 ml of blood were added immediately after 
collection. To prepare the samples with graded SaO2 levels for DWP-OCT measurement we 
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ml of blood to achieve a sample with SaO2 = 0%. Oxygenated arterial blood was mixed with 
the 0% SaO2 blood in different proportions to achieve intermediate SaO2 levels of 18.5%, 
58.4%, 84.1% and 92.8%. Blood samples with desired SaO2  levels were kept at room 
temperature (22°C) in 2.5 ml sealed cuvettes for at least 20 min prior to DWP-OCT 
measurement to avoid small drifts in oxygenation [28]. The PTFE conduit with a 330 µm 
inner diameter and 480 µm outer diameter (SUBL-190, Braintree Scientific Inc.) was 
fastened to the surface of a 1 mm thick glass slide using epoxy and filled with blood at a 
prepared SaO2 level using a 1 ml syringe. Remaining blood in the syringe was utilized for 
simultaneous reference measurement of SaO2  by the avoximeter. Manufacturer specified 
SaO2 measurement precision of the avoximeter is 1%. After DWP-OCT measurement of 
each blood sample, the phantom vessel was flushed with distilled water and dried with forced 
air. 
2.2 Laser Excitation 
A Mira 900 Ti:Al2O3 laser system (Coherent Inc., Santa Clara, CA) was used in continuous 
wave mode to induce optical pathlength (op) changes in blood samples (Fig. 1). First, the 
laser was tuned to oscillate at 765 nm as verified by an optical spectrometer (USB2000, 
Ocean Optics, Dunedin, FL). Light emitted from the laser was coupled into a 0.22 NA 50 µm 
core-diameter multimode fiber using an optical collimator (f = 11.23 mm). Light output from 
the fiber was collimated with a bi-convex lens (f = 25.4 mm) and intensity modulated (fo = 42 
Hz) with a mechanical chopper. A small fraction (4%) of excitation light was utilized as an 
intensity reference and coupled into a Si photodetector (2032, New Focus, Irvine, CA) using 
a thin glass cover slip and lens (Fig. 1). The intensity reference signal from the Si 
photodetector was digitized with a 14-bit analog-to-digital converter (USB-6009, National 
Instruments, Austin, TX) at 100 S/s and stored in computer memory for computation of SaO2 
levels. 
The end face of the excitation laser output fiber was placed 1 mm below the glass slide 
underlying the blood sample giving a 900 µm beam-diameter on the vessel phantom. The 
relatively wide excitation beam diameter allowed easy co-registration of OCT and laser 
excitation beams. Light from the MIRA laser was blocked with a shutter when DWP-OCT 
data was not being recorded. To simultaneously irradiate the blood sample and record the 
intensity reference signal, the shutter was opened for 15-20 seconds and DWP-OCT data was 
recorded while excitation light (765 nm) impinged on the blood sample for 4-6 seconds. The 
measurement procedure using 765 nm excitation light was repeated three to five successive 
times for each blood sample. The MIRA laser was then tuned to 800 nm and the 
measurement procedure was repeated for the same blood sample as with 765 nm excitation. 
Following laser excitation at 765 nm and 800 nm, blood in the phantom vessel was removed, 
the lumen cleaned and replaced with blood prepared at another SaO2 level. The measurement 
procedure was repeated by exciting the blood sample at 765 nm and 800 nm and recording 
both DWP-OCT and laser excitation intensity reference data. The average laser excitation 
power at each blood sample was fixed at 23 mW (765 nm) and 51 mW (800 nm). The higher 
power at 800 nm was due to limited emission capability of the MIRA laser at 765 nm. 
2.3. Phase Sensitive OCT system 
A phase sensitive (PhS) OCT system (Fig. 1) was used to measure nanometer and sub-
nanometer scale changes in optical pathlength in the sample in response to laser excitation. 
The PhS-OCT system has been described in detail previously [23]. Briefly, the PhS-OCT 
system uses a 20 kHz swept source laser with a central wavelength of 1328 nm and 
bandwidth of 100 nm (HSL-2000, Santec USA Corp., Hackensack, NJ) and employs a 
common-path geometry. The system provides excellent phase stability (65 pm at a 280 µm 
depth) and low degradation of optical pathlength sensitivity with depth (0.16 nm/mm). 
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diagram of the blood phantom, M-mode intensity map, intensity A-scan and M-mode phase 
map of the phantom vessel filled with blood is shown in Fig. 2A, Fig. 2B, Fig. 2C and Fig. 
2D respectively. 
 
Fig. 2. A) Blood vessel phantom geometry, B) M-mode intensity map, C) intensity OCT A-
scan, and D) M-mode phase map. The lines of constant phase in the M-mode phase map and 
spikes on the intensity OCT map and A-scan correspond to: 1 – the upper air-vessel interface 
(optical pathlength, op = 73 µm), 2 – upper vessel-blood interface (op = 187 µm), 3 – lower 
blood-vessel interface (op = 572 µm), 4 – vessel-epoxy interface (op = 676 µm), 5 - epoxy-
glass slide interface (op = 749 µm). The blue arrows in the Intensity map indicate boundary 
between RBC poor blood plasma and RBC dense layer due to sedimentation. 
2.4. Depth-resolved Photothermal OCT signal 
Depth-resolved Photothermal OCT signals corresponding to variation of optical pathlength 
(op) was measured at five depths in the blood sample (Fig. 2): 1 – the upper air-vessel 
interface (op = 73 µm), 2 – upper vessel-blood interface (op = 187 µm), 3 – lower blood-
vessel interface (op = 572 µm), 4 – vessel-epoxy interface (op = 676 µm), 5 - epoxy-glass 
slide interface (op = 749 µm). The intensity signal-to-noise ratio (SNR), magnitude of op 
change induced by excitation laser light near the isobestic point (800 nm) and SNR of the 
detected op at the five depths are summarized in Table 1. 
Table 1. Typical signal and noise levels at five depths (SaO2 = 18%) shown in Fig. 2. 
Here dB is computed as 20•Log10(SNR). 
    765 nm     800 nm 
Depth  Intensity SNR (dB)  OP amplitude ( nm)  OP SNR (dB)     OP amplitude ( nm)  OP SNR (dB) 
1  70.4 ± 2.6  0.15 ± 0.0048  36.6 ± 1.1     0.24 ± 0.020  40.6 ± 1. 5 
2  50.3 ± 2.7  0.21 ± 0.11  12.5 ± 4.4     0.20 ± 0.059  12.9 ± 2.5 
3  32.1 ± 4.0  1.21 ± 0.23  21.2 ± 0.96     1.70 ± 0.10  26.0 ± 4.4 
4  48.3 ± 4.1  1.26 ± 0.065  36.5 ± 5.8     1.70 ± 0.071  43.1 ± 0.91 
5  79.7 ± 3.78  1.29 ± 0.027  39.0 ± 7.8     1.74 ± 0.048  47.4 ± 1.2 
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optical pathlength changes of probe light propagating through overlying layers [24]. To 
measure SaO2 levels in a blood sample, influence of optical pathlength changes in overlying 
layer(s) must be excluded and requires measurement of differential optical pathlength (Δop) 
between two longitudinal points. To measure SaO2  levels in the phantom vessel, Δop 
between the lower blood-vessel interface (depth 3) and the upper vessel-blood interface 
(depth 2) was computed. The computed value represents SaO2 level of blood in the vessel 
lumen. For reference, SaO2 levels were also computed from Δop between depths 1 and 5 
which provide higher SNR OCT signal intensities (Table 1). DWP-OCT data was acquired 
for 8-12 seconds. Within the DWP-OCT data acquisition time period the shutter was opened 
to expose the blood sample with laser radiation for 4-6 seconds. A one-second time interval 
of DWP-OCT data including laser excitation of the sample was used for calculations of SaO2 
levels. The 1 second segment time interval was at least 1 second following opening of the 
shutter to remove transient effects. After subtracting the linear trend, the 1 second time-
interval of DWP-OCT data (Fig. 3A) was Fourier transformed to compute the amplitude of 
differential optical pathlength at 42 Hz (Δop(fo = 42Hz), Fig. 3B). 
 
Fig. 3. A) Optical pathlength (op) variation at depth 5 (linear trend subtracted) in response to 
laser excitation (blood-gas SaO2 = 18.5%, excitation at 800 nm at 42 Hz). B) Amplitude of op 
variation at depths 1-5 vs laser excitation modulation frequency (grey trace in Fig. 3B is 
magnitude of fast Fourier transform of op depicted in A). 
2.5. Blood Oxygenation (SaO2) Levels 
Photothermal OCT is capable of measuring laser-induced variation in op on the nanometer 
scale in scattering objects such as human tissues [24–27]. In DWP-OCT, two laser excitation 
wavelengths are used to induce optical pathlength (op) changes in the sample. Difference in 
the absorption spectra between oxy- and deoxy-hemoglobin in two spectral regions (765 nm 
and 800 nm, see inlet in Fig. 1) may be utilized by DWP-OCT to determine blood 
oxygenation levels (SaO2). 
Since magnitude of op  variation in response to clinically relevant excitation laser 
irradiance levels (mW and tens of mW) is small (0.2 nm – 2 nm), a linear relationship exists 
between differential optical pathlength (Δop) and fluence of excitation light absorbed by 
blood over a half-period (τ = 1/2fo) of laser excitation: 
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1
11 1,
a l op k I e
µ τ
− ∆= −    
  ( )
2
22 1,
a l op k I e
µ τ
− ∆= −   (1) 
where l is the vessel diameter, Δop1(2) is the differential optical pathlength between depths 2 
and 3 (blood vessel) due to laser excitation (subscript 1 denote laser excitation at λ1 = 765 nm 
and subscript 2 denotes laser excitation at λ2 = 800 nm), k - is a constant coefficient, I1(2)τ – 
fluence of excitation light on the phantom vessel, τ = 1/2fo = 0.012 second is half period of 
modulation of laser excitation light, I1(2) is intensity amplitude of excitation light incident on 
the phantom vessel, µa1(2) – is absorption coefficient of the blood sample at 765 nm(1) and 
800 nm(2). Neglecting absorption in blood by any constituent except for hemoglobin, gives 
algebraic expressions for the absorption coefficients of blood at 765 nm and 800 nm: 
  11 1 , a dd oo cc µα α = +    
  22 2 , a dd oo cc µα α = +   (2) 
where  co  is concentration of oxygenated hemoglobin (mM), cd  is concentration of 
deoxygenated hemoglobin (mM), αo1(2)  is tabulated molar extinction of oxygenated 
hemoglobin (cm
−1mM
−1, see inlet in Fig. 1),  αd1(2)  is tabulated molar extinction of 
deoxygenated hemoglobin (cm
−1mM
−1). Equation (2) may be rewritten in terms of oxygen 
saturation (SaO2 = co/(co + cd)) and total hemoglobin concentration (THb = co + cd): 
  ( ) 1 21 1 1 , a od d THb SaO µ αα α = −+       
  ( ) 2 22 2 2 . a od d THb SaO µ αα α = −+      (3) 
When absorption length of excitation light is much longer than the vessel diameter 
( 1,2 1 a l µ << ), differential optical pathlength (Eq. (1) simplifies to 
  1 11 , a op k I l τµ ∆=     
  2 22 . a op k I l τµ ∆=    (4) 
Blood oxygen saturation level (SaO2) obtained from the ratio  12 / op op ∆∆  using Eqs. (3) 
and 4 is written as 
 
1 12 2
2
2121
,
dd
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−
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   (5) 
where 
 
12
12
21
.
op I
op I
χ
∆
=
∆
   (6) 
By measuring differential optical pathlength (Δop) in blood at two wavelengths 
normalized by incident excitation light intensities, SaO2 levels can be computed directly. 
3. Results and Discussion 
The dependence of op  and  Δop  magnitude per 1 mW of excitation power on reference 
avoximeter oxygenation for 765 nm and 800 nm at different depths is shown in Fig. 4. The 
magnitude of op  at the upper air-vessel interface (depth 1) was equivalent (within 
experimental error) to that at the upper vessel-blood interface (depth 2) and magnitude of op 
at the lower blood-vessel interface (depth 3) was equivalent (within experimental error) to 
that at the epoxy-glass slide interface (depth 5) and vessel-epoxy interface (depth 4). Depth 4 
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magnitude at depth 4 for a specific SaO2 (18%) can be found in Table 1. Note the magnitude 
of op at depths 3, 4 and 5 are 8-10x larger than those at depths 1 and 2. The order of 
magnitude increase of op for probe light double passed through the blood as compared with 
op values for light not propagating through blood is discussed below. 
 
Fig. 4. Optical path (op) variation amplitude per 1 mW power of excitation light vs. reference 
avoximeter readings. OP variations are at depths 1, 2, 3, 5 for A) 765 nm and B) 800 nm 
excitation light. ΔOP variations between depths 3 and 2 (Δop32) and between depths 5 and 1 
(Δop51) that was used for calculating of SaO2 levels for C) 765 nm and D) 800 nm excitation 
light. Error bars are mean ± SD, n = 3-5. 
As observed in Fig. 4, op for all depths decreased significantly with increasing SaO2 for 
excitation at 765 nm and was almost independent of SaO2 at 800 nm. The relative change in 
op magnitude with SaO2 increasing from 0% to 100% was estimated using a linear fit of the 
data in Fig. 4. At 765 nm excitation (Fig. 4A), the relative decrease of op was 2.2 - 2.9, 
times, whereas the Hb absorption coefficient is 2.3 times higher than the HbO2 absorption 
coefficient at 765 nm (Table 2). At 800 nm excitation (Fig. 4B), the relative change of op 
over the tested range of SaO2 levels was within ± 10% as expected (i.e., Hb absorption is 
1.08 times lower than HbO2 absorption) except for depth 2. At depth 2, the relative increase 
in op magnitude was 1.4x versus 1.08x expected due to a lower op signal-to-noise ratio (SNR 
OP, Table 1). 
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Parameter  Fluence* (J/cm
2)  HbO2 molar 
extinction 
(cm
−1mM
−1) 
Hb molar 
extinction 
(cm
−1mM
−1) 
HbO2 absorption 
coefficient** 
(mm
−1) 
Hb absorption 
coefficient** 
(mm
−1) 
765 nm  Φ01 = 0.043  αo1 = 0.616  αd1 = 1.435  µao1 = 0.11  µad1 = 0.25 
800 nm  Φ02 = 0.096  αo2 = 0.816  αd2 = 0.762  µao2 = 0.14  µad2 = 0.13 
*Calculated using half period of modulation of laser excitation light τ = 0.012 second 
**Calculated suggesting SaO2  = 100% for HbO2  and SaO2  = 0% for Hb and using typical concentration of 
hemoglobin in porcine blood THb = 1.77 mM (11.4 g/dL, hemoglobin molecular weight MW = 64500 g/mole) [30]. 
SaO2  levels were computed using Δop  between depths 3 and 2 (Δop32) and between 
depths 5 and 1 (Δop51). For 765 nm excitation Δop was estimated to decrease with increasing 
SaO2 levels (from 0% to 100%) by 2.5 for Δop32 and 2.9 times for Δop51 (Fig. 4C). For 800 
nm excitation Δop was almost constant with increasing SaO2 levels (from 0% to 100%) and 
decreased slightly (by 1.1x) for both Δop32 and Δop51 (Fig. 4D). Note the standard deviations 
for  Δop32  at 765 nm excitation were much higher (3.7 times in average) than standard 
deviations for Δop51 due to low OP SNR at depths 2 and 3 for high SaO2 levels where the 
hemoglobin absorption is small (Table 2). For 800 nm excitation, the standard deviations for 
Δop32 and Δop51 were very close since excitation power was more than 2 times greater than 
that at 765 nm and smallest hemoglobin absorption coefficient at 800 nm (SaO2 = 0%) is 
20% greater than the smallest absorption coefficient for 765 nm light (SaO2 = 100%). 
Average deviation of SaO2 levels (Eq. (5) in the blood sample measured with DWP-OCT 
using Δop32 from depths 2 and 3 differ from the reference avoximeter values by less than 
10.1% while SaO2 values determined from depths 1 and 5 differ by less than 6.3% (Fig. 5). 
Higher precision SaO2 measurements using Δop51 between depths 5 and 1 as compared to 
depths 3 and 2 is due to higher SNR of op amplitude at depth position 5 compared to 3 and 
depth position 1 compared to 2 (Fig. 5). The results demonstrated application of DWP-OCT 
to measure depth-resolved SaO2 in a phantom blood vessel. 
 
Fig. 5. SaO2 levels measured with DWP-OCT (765 nm and 800 nm excitation light) vs. 
reference avoximeter readings. DWP-OCT SaO2 levels were calculated from measured Δop51 
between depths d5-d1 (diamonds) and Δop32 between depth d3-d2 (squares) Error bars are 
mean ± SD, n = 3-5. 
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amplitude (Table 1, column 4 (OP SNR) for 765 nm excitation wavelength and column 6 
(OP SNR) for 800 nm). To facilitate interpretation, data in Table 1 is presented in graphical 
form (Fig. 6). OP SNR at a given depth was dependent on the combined effect of OCT 
intensity SNR and op amplitude. Highest OP SNR (purple in Fig. 6) was achieved at depth 5 
where large-value intensity SNR was coupled with large-value (nanometer-scale)  op 
amplitude. Lowest OP SNR was achieved at depth 2 where medium-value intensity SNR was 
coupled with low-value (subnanometer-scale)  op  amplitude. Large value OP SNR was 
achieved at depths 1 and 4. At depth 1 large-value intensity SNR was coupled with low-value 
op amplitude while at depth 4 medium-value intensity SNR was coupled with large-value op 
amplitude. Finally, medium-valued OP SNR was achieved at depth 3 where low-value 
intensity SNR was coupled with large-value op amplitude. 
 
Fig. 6. OCT Intensity SNR, op SNR and op amplitude measured at five depths indicated in 
Fig. 2. The op SNR and op amplitude was measured at A) 765 nm and B) 800 nm excitation 
wavelengths. 
Two levels of measured op  magnitude are observed (Figs. 4 and 6  and  Table 1) in 
response to laser excitation: op in the subnanometer range (0.15 nm - 0.24 nm) at depths 1 
and 2, and op in nanometer range (1.21 nm – 1.74 nm) at depths 3, 4 and 5. Additionally, 
within experimental error, op  magnitudes are equivalent for depths 1 and 2 (in the 
subnanometer range) and for depths 3, 4 and 5 (in the nanometer range). Thus, only two 
mechanisms result in op variation: one for depths 1 and 2 and another for depths 3, 4 and 5. 
In general, the thermally induced op variations can be represented by a sum of thermoelastic 
expansion (dL/dT) and thermorefractive effect (dn/dT) [24]. Since op magnitude is of the 
same order for depth 1 (where probe light did not pass through the phantom wall) and depth 
2 (where probe light propagated double pass through the phantom wall) negligible absorption 
of excitation light occurred in the phantom wall and op  variation at these depths were 
induced dominantly by thermoelastic expansion of the vessel wall. OCT probe light reflected 
from depths 3, 4 and 5 propagates double-pass through the blood while OCT probe light 
returned from depths 1 and 2 do not propagate through the blood. Therefore the 8-10x larger 
op  variation observed at depths 3-5 as compared with depths 1 and 2 are due to a 
thermorefractive effect in blood. In conclusion, at depths 3-5 both thermoelastic and 
thermorefractive effects were present and effected op, at depths 1 and 2 only a thermoelastic 
effect due to expansion of blood was present. Thermorefractive effect contributed a 7-9x 
greater op variation than that due to thermoelastic effect. 
The model proposed here assumes: a)  max 1 a l µ << , where  max a µ  is maximum absorption 
coefficient in the working range of excitation light and SaO2  levels; b) excitation 
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wavelengths is equal. Conditions a) and b) are satisfied here: a) if SaO2 levels are measured 
in a blood vessel with l = 300 µm, maximal absorption coefficient µamax = µad1 = αd1THb = 
0.25 mm
−1 (Table 2), where 1 d α = 1.435 cm
−1mM
−1 [29] and typical values in porcine blood 
of THb = 1.77 mM (11.4 g/dL) [30] give µamaxl = 0.075 <<1 consistent with assumption a; b) 
optical throughput of 765 nm and 800 nm light into the blood vessel is equivalent because 
light diffraction and scattering are nearly equal. 
Additionally the model assumes that heat produced by light absorption of hemoglobin is 
confined within the heating volume over a half period of excitation light (τ = 1/2fo = 12 ms). 
Therefore, for the static phantom blood vessel utilized in experiments reported here, thermal 
relaxation time τth should be longer than τ. This condition was satisfied since τth = d
2/(16α) = 
62 ms and is 5.2 times longer than τ = 12 ms. Here α = 1.1•10
−3 cm
2s
−1 [31] is thermal 
diffusivity of blood and d = 0.33 mm is diameter of the phantom blood vessel. The thermal 
confinement condition may be broken if blood in the vessel is flowing. In the case of flowing 
blood, the method requires half period of excitation light τ is shorter than the time for blood 
to flow through the beam diameter (bd = 0.9 mm) of excitation light (τf = bd/vb,) where vb is 
the blood flow velocity. This condition is satisfied in the experimental setup described here if 
the blood flow velocity is significantly less than 75 mm/s. 
Estimated temperature increase over a half period (on-time) of laser excitation is [32] 
 
2 02 0.033
ad Φ
c
TK
µ
ρ
∆= =    (7), 
where  ΔT  is the maximal temperature increase due to absorption of excitation light by 
hemoglobin in the blood sample; ρc = cp•ρ = 3.8 J•cm
−3•K
−1 is volumetric heat capacity of 
blood, cp is specific heat capacity of blood [33], ρ = 1060•10
−6 kg
−1•cm
−3 is density of the 
blood [34]. Parameters  2 ad µ  and Φ02 = I02τ are shown in Table 2. 
Additional to temperature oscillations at the excitation frequency as described in Eq. (7), 
the cumulative effect of light absorption was responsible for the observed slow temperature 
increase (Fig. 7). The effect was observed in photothermal OCT studies using nanoparticles 
reported by Adler et al. [25] and Skala et al. [26]. To estimate temperature increase ΔT1s over 
a 1 second time period due to the cumulative effect of light absoprtion, average optical 
pathlength Δop1s over one second and Δopτ over half period (on-time) of laser excitation 
were calculated: 
  ( )
1
1 0 16 0 073 .
s
s
op
T T. .K
opτ
∆
∆ = ∆= ±
∆
   (8). 
To estimate the average drift Δop1s, from the original signal the running average over the 
period of excitation light was applied and Δop1s was calculated as Δop1s = op1s- op0s as 
shown in the Fig. 7, where op0s is the optical pathlength at the beginning and op1s at the end 
of the 1 second time segment. Since the temperature increase in the experiments was well 
below 1 K as following from Eqs. (7) and (8) no structural modifications are believed to 
occur in blood. 
Equations (5) and (6) indicate that measurement of SaO2 requires that ratio of excitation 
light intensities (I2/I1) be monitored accurately. Since differential optical pathlength at the 
two laser excitation wavelengths (Δop1 and Δop2) was measured at fo = 42 Hz, I1 and I2 were 
monitored by a Si photodetector at 42 Hz. Error of DWP-OCT measured SaO2  levels 
(ΔSaO2) depends on the SaO2  level, relative errors in optical pathlength variation 
( 1,2 op δ  ∆  ) and relative uncertainty in laser excitation intensities (δΙ) at the blood sample: 
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Fig. 7. Optical pathlength (op) variation at depth 5 shown in Fig. 3 where linear trend is not 
subtracted in response to laser excitation (blood-gas SaO2 = 18.5%, excitation at 800 nm at 42 
Hz). The orange line without oscillations is a running average over one period of oscillations. 
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   (9) 
where αo1, αd1, αo2 and αd2 are taken from Table 2 and  [ ] [ ] 12 1 2 2 op op I δχ δ δ δ =∆ +∆ +  is the 
relative error in parameter χ12. Here relative error in optical pathlength δ[Δop1] = (2.7 ± 
2.4)% and δ[Δop2] = (0.4 ± 0.2)% were derived from op measurements. Using measured 
SaO2 values and their variation from reference values, relative uncertainty for 765 nm and 
800 nm laser excitation intensities was assumed equal and is estimated from Eq. (9) at δI = 
(2.1 ± 2.1)%. 
Previous studies of non-invasive depth-resolved blood oxygenation measurements using 
intensity based spectral OCT revealed a number of challenges due to the scattering properties 
of blood including multiple scattering [35], highly forward scattering by RBC’s [36], 
Brownian movement of the scattering centers [37–39] and blood sedimentation in phantoms 
[40]. Light scattering is unpredictable due to dynamic intra- and inter-subject changes, and 
large variation in detected intensity due to speckles. Boyer et al. [41] showed and Skala et al. 
confirms [26] that photothermal approach is insensitive to scattering. Accordingly, in our 
studies we did not observe significant op noise in the signal bandwidth due to fluctuations in 
scattering. OP  signals recorded here depend primarily on light absorption and excitation 
fluence in the irradiated sample volume. Differential modification of fluence at the two 
excitation wavelengths (765 nm and 800 nm) by scattering in the irradiated sample was not 
observed. As noted by Tuchin et al. [40] we also observed some blood sedimentation (the 
boundary between plasma and RBC indicated by arrows on the Fig. 2B) but this effect did 
not influence the op measurements. 
Influence of Brownian movement of RBC was noted as a slow modulation of the 42 Hz 
signal (“radio”) frequency of the op (Fig. 3A and Fig. 7). The effect introduced additional 
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modulation frequency was approximately an order of magnitude faster than the slow 
modulation due to Brownian movement. 
Precision of DWP-OCT SaO2 measurements can be improved by: 1) decreasing relative 
uncertainty of laser excitation intensity (δI) incident on the sample; 2) decreasing relative 
error in optical pathlength (δ[Δop]) by utilizing a higher modulation frequency of laser 
excitation thus detuning from low-frequency phase drift artifacts; 3) increasing number of 
laser excitation wavelengths to more than two; or 4) increasing number of op measurements 
in the vessel wall at each laser excitation wavelength. 
In conclusion, we introduced DWP-OCT to measure SaO2  levels in a blood vessel 
phantom. The approach was demonstrated in a vessel phantom containing stationary blood 
and provides good agreement with an established reference technique. Compared to existing 
techniques, DWP-OCT provides some important features for SaO2 measurement including 
depth-resolved measurements and capability to measure SaO2  levels in discrete vessels. 
DWP-OCT is based on detection of optical pathlength (op) changes in response to absorption 
of excitation light and is therefore free from high variation of depth-resolved scattering-based 
spectral OCT approaches [15,19]. Moreover, scattering properties of blood do not influence 
the accuracy of DWP-OCT SaO2 measurements and spectral- and depth-resolution provided 
by DWP-OCT are not compromised. Moreover, the model equation (Eq. (6) developed to 
determine DWP-OCT SaO2 levels avoids computationally intensive Monte Carlo simulations 
utilized in previous approaches. High sensitivity of DWP-OCT to measure optical pathlength 
(op) changes in blood allows application of relatively low-level laser excitation intensities. 
The demonstrated results suggest that further investigation of DWP-OCT in pre-clinical 
models is warranted. 
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